Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Targeting the programmed death-1 pathway in lymphoid neoplasms.

Publication ,  Journal Article
Ok, CY; Young, KH
Published in: Cancer Treat Rev
March 2017

Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. Activated effector T-cells, which kill cancer cells, can be affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2. PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e. interferon gamma) or intrinsic signals, such as genetic aberrations involving 9p24.1, latent Epstein-Barr virus infection, PD-L1 3'- untranslated region disruptions, and activated Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Anti-PD-1 therapy improves the overall response rate to treatment in patients with lymphoid neoplasms, particularly relapsed/refractory classical Hodgkin lymphoma. Inspired by their success in treating patients with classical Hodgkin lymphoma, medical practitioners have expanded PD-1 therapy, given as a single therapy or in combination with other drugs, to patients with other types of lymphoma. In this review, current clinical trials with anti-PD-1 or anti-PD-L1 drugs are summarized. The results of numerous clinical trials will broaden our understanding of PD-1 pathway and shall expand the list of patients who will get benefit from these agents including those who suffer from lymphoid neoplasms.

Duke Scholars

Published In

Cancer Treat Rev

DOI

EISSN

1532-1967

Publication Date

March 2017

Volume

54

Start / End Page

99 / 109

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Programmed Cell Death 1 Receptor
  • Programmed Cell Death 1 Ligand 2 Protein
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Lymphoma
  • Humans
  • B7-H1 Antigen
  • Antibodies, Monoclonal
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ok, C. Y., & Young, K. H. (2017). Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev, 54, 99–109. https://doi.org/10.1016/j.ctrv.2017.01.009
Ok, Chi Young, and Ken H. Young. “Targeting the programmed death-1 pathway in lymphoid neoplasms.Cancer Treat Rev 54 (March 2017): 99–109. https://doi.org/10.1016/j.ctrv.2017.01.009.
Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017 Mar;54:99–109.
Ok, Chi Young, and Ken H. Young. “Targeting the programmed death-1 pathway in lymphoid neoplasms.Cancer Treat Rev, vol. 54, Mar. 2017, pp. 99–109. Pubmed, doi:10.1016/j.ctrv.2017.01.009.
Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017 Mar;54:99–109.
Journal cover image

Published In

Cancer Treat Rev

DOI

EISSN

1532-1967

Publication Date

March 2017

Volume

54

Start / End Page

99 / 109

Location

Netherlands

Related Subject Headings

  • T-Lymphocytes
  • Programmed Cell Death 1 Receptor
  • Programmed Cell Death 1 Ligand 2 Protein
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Lymphoma
  • Humans
  • B7-H1 Antigen
  • Antibodies, Monoclonal
  • 1112 Oncology and Carcinogenesis